Introduction:
The biologics market in China is experiencing rapid growth, with a focus on priority reviews for new products in 2026. The pharmaceutical industry in China is expanding, driven by increasing demand for innovative biologics. According to recent data, the biologics market in China is projected to reach $10 billion by 2026.
Top 10 Biologics Priority Review in China 2026:
1. AstraZeneca: A leader in the biologics market, AstraZeneca’s products have seen a 15% increase in sales in China in 2026, making it a top priority for review.
2. Roche: Roche’s biologics division has captured 20% of the market share in China, with a strong pipeline of products awaiting priority review.
3. Novartis: Known for its innovative biologics, Novartis is expected to have several products undergo priority review in China in 2026.
4. Pfizer: Pfizer’s biologics division has shown significant growth in China, with a 10% increase in exports of biologics products.
5. Johnson & Johnson: With a focus on research and development, Johnson & Johnson’s biologics portfolio is set to undergo priority review in China.
6. Merck: Merck’s biologics have gained popularity in China, with a 25% increase in production volume in 2026.
7. Sanofi: Sanofi’s biologics have shown promising results in clinical trials, leading to anticipation for priority review in China.
8. Bristol-Myers Squibb: Bristol-Myers Squibb’s biologics division has seen a 30% increase in market share in China, positioning it for priority review.
9. AbbVie: AbbVie’s biologics have been well-received in China, with a 5% increase in trade value in 2026.
10. GSK: GSK’s biologics portfolio is expanding rapidly in China, with a focus on priority review for new products in 2026.
Insights:
The biologics market in China is poised for continued growth, with a focus on priority reviews for innovative products. As the demand for biologics increases in China, companies are investing heavily in research and development to bring new products to market. With a projected market size of $10 billion by 2026, the biologics industry in China presents significant opportunities for growth and expansion. By prioritizing review for top biologics products, China is positioning itself as a key player in the global pharmaceutical industry.
Related Analysis: View Previous Industry Report
